Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market.

Biogen Inc. (NASDAQ:BIIB) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It has begun dosing in the ...

One of two newly approved drugs for Alzheimer’s disease has been submitted for National Health Insurance (NHI) coverage, and ...

JPMorgan cut its price target on Sage Therapeutics to $8.5 from $11 based on the recently announced buyout by Supernus ...

The Global Monoclonal Antibody Therapeutics Market is valued at approximately USD 205.09 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 15.0% over the forecast ...